Trastuzumab biosimilar - DM Bio
Alternative Names: DA-3111; DMB 3111Latest Information Update: 28 May 2025
At a glance
- Originator Dong-A Socio Holdings; Meiji Seika Pharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Gastric cancer; HER2 positive breast cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Gastric-cancer in South Korea (IV, Infusion)
- 28 May 2025 No recent reports of development identified for phase-I development in Gastric-cancer(In volunteers) in Japan (IV, Infusion)
- 28 May 2025 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer in South Korea (IV, Infusion)